Test a phone tool for self-checks in NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study tests a digital (phone) tool that helps people with NMOSD do unsupervised self-assessments between clinic visits. It looks at how well the tool works and whether it is safe and understandable for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have NMOSD confirmed as AQP4-positive (an NMOSD subtype)
- Be on stable NMOSD treatment (no change for at least 6 months before joining)
- Have no NMOSD relapse in the past 3 months
- Be able to use a personal smartphone (iPhone iOS 13+ or Android 8+)
- Have enough daily ability and reading understanding to complete the phone assessments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a digital tool (NMS Assist) to help people with Parkinson's and their caregivers track and manage non-motor symptoms like mood, sleep, and thinking changes. Participation takes place from home using a smartphone or tablet.
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This study tests a smartphone or computer app designed to help people with long-term health conditions like arthritis, heart disease, or stroke manage their own recovery. The goal is to see if using the app improves daily living and reduces disability.
This study tests whether a new stem cell treatment (CE211NS21) is safe and well-tolerated in patients who have had a recent serious attack from NMOSD, a rare neurological condition. The treatment aims to reduce disability and vision loss from this disease.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.